Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model
about
Antimicrobial Activity and Resistance: Influencing Factors.Emergence of resistant Klebsiella pneumoniae in the intestinal tract during successful treatment of Klebsiella pneumoniae lung infection in rats.In vivo evaluation of mutant selection window of cefquinome against Escherichia coli in piglet tissue-cage model.Effect of probiotics on enrofloxacin disposition in gastrointestinal tract of poultry.Bacterial Species-Specific Activity of a Fluoroquinolone against Two Closely Related Pasteurellaceae with Similar MICs: Differential In Vitro Inoculum Effects and In Vivo EfficaciesPharmacokinetics/pharmacodynamics of marbofloxacin in a Pasteurella multocida serious murine lung infection model.Impact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infectionEmergence and spread of antibiotic resistance following exposure to antibiotics.Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal floraSusceptibility and PK/PD relationships of Staphylococcus aureus strains from ovine and caprine with clinical mastitis against five veterinary fluoroquinolones.A large potentiation effect of serum on the in vitro potency of tulathromycin against Mannheimia haemolytica and Pasteurella multocida.Infection-stage adjusted dose of beta-lactams for parsimonious and efficient antibiotic treatments: A Pasteurella multocida experimental pneumonia in mice.In Vitro Resistance Selection in Shigella flexneri by Azithromycin, Ceftriaxone, Ciprofloxacin, Levofloxacin, and Moxifloxacin.Pharmacokinetic/pharmacodynamic integration and modelling of amoxicillin for the calf pathogens Mannheimia haemolytica and Pasteurella multocida.Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.Pharmacokinetic and pharmacodynamic modelling of marbofloxacin administered alone and in combination with tolfenamic acid in calves.Correlation of PK/PD Indices with Resistance Selection for Cefquinome against Staphylococcus aureus in an In Vitro Model.Relationship between danofloxacin PK/PD parameters and emergence and mechanism of resistance of Mycoplasma gallisepticum in In Vitro model
P2860
Q33790192-0D7D2BDD-C124-48E8-B682-FE97D79A7A4AQ33962866-6F62082C-97EC-4ACA-A02D-43AB73BC9A17Q34788573-00A6A67A-49E2-43F8-B252-A109906BD543Q35604689-56C96C9A-1CD4-4E63-879C-902EE0B4C69BQ35823020-6DA6C487-F723-40E0-B4BC-F191D81A60CDQ35859460-D620B503-2058-4C01-B5E0-0F563D41C2BDQ36401623-74FF50BC-5120-4F1B-BC5F-5D6F1B6C43F3Q37896674-4B67DC3F-0253-4F17-92AC-07B820644023Q38324219-25BE469D-4D69-4917-A8F7-6A2E4887C504Q38954542-DDF5EF2C-AD8E-469C-87C3-6ABC6E48AE98Q39149738-D2AA2E65-AE32-4897-9F46-3496DA2F11BAQ40106417-92675B99-7E29-43EB-A037-F4AF2F0A99A0Q40220956-3815A488-085F-42BC-A811-9A3D451EAFADQ41453107-A8322544-7523-4AFA-A1E4-4F9B911EF3D7Q42612081-3A70D864-7B58-48A4-A4A0-C6B28BEDA893Q46518946-E660920D-20FF-4F53-BF18-31C9E5D0A2D7Q54187518-789BDFD1-C0E6-4D82-857B-2431379A28CFQ58696539-DCEB3684-754D-4CF1-BB54-46C8351BDA59
P2860
Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetic/pharmacodynami ...... high bacterial infection model
@en
Pharmacokinetic/pharmacodynami ...... igh bacterial infection model.
@nl
type
label
Pharmacokinetic/pharmacodynami ...... high bacterial infection model
@en
Pharmacokinetic/pharmacodynami ...... igh bacterial infection model.
@nl
prefLabel
Pharmacokinetic/pharmacodynami ...... high bacterial infection model
@en
Pharmacokinetic/pharmacodynami ...... igh bacterial infection model.
@nl
P2860
P356
P1476
Pharmacokinetic/pharmacodynami ...... high bacterial infection model
@en
P2093
Anne-Sylvie Kesteman
Pierre-Louis Toutain
P2860
P304
P356
10.1128/AAC.01347-08
P407
P577
2009-06-01T00:00:00Z